The US Food and Drug Administration has lifted a clinical hold on research into SRP-5051, a candidate under development by rare disease company Sarepta Therapeutics (Nasdaq: SRPT).
The investigational PPMO therapy is being tested as an option for people with Duchenne muscular dystrophy (DMD) who are amenable to exon 51 skipping.
The hold in Part B of the MOMENTUM study came after a serious adverse event of hypomagnesemia, earlier in the year.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze